.Nature Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a typical consequence of 11 months, individuals with metastatic intestinal tumors that acquired biomarker-matched therapies based on distributing growth DNA profiling revealed a greater clinical benefit than those acquiring unparalleled therapy.